on HBM Healthcare Investments AG (isin : CH0012627250)
HBM Portfolio Company Yellow Jersey Therapeutics to Be Acquired for $1.25 Billion
HBM Healthcare Investments AG announced that Yellow Jersey Therapeutics, a portfolio company, will be acquired by Johnson & Johnson for $1.25 billion. This deal validates the science and innovation of the Swiss biotech company.
The acquisition will increase HBM's net asset value per share by CHF 8.70, representing a 3.5% rise. HBM expects a cash inflow of $78 million from the transaction. Yellow Jersey Therapeutics holds NM26, a Phase 2-ready bispecific antibody targeting atopic dermatitis.
The transaction is set to close in the second half of 2024. HBM retains an 8% stake in Numab Therapeutics, which focuses on oncology and inflammatory disease therapies through its proprietary platforms.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HBM Healthcare Investments AG news